Age Dependence of the Influence of Methylenetetrahydrofolate Reductase Genotype on Plasma Homocysteine Level

American Journal of Epidemiology

Volumn 158, Issue 9, 2003, Pages 871-877

  Spotila, Loretta D ^a   Jacques, Paul F ^b   Berger, Peter B ^c   Ballman, Karla V ^c   Ellison, R Curtis ^d   Rozen, Rima ^e  

^a DREXEL UNIVERSITY   (United States)

^b TUFTS UNIVERSITY   (United States)

^c MAYO CLINIC   (United States)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e MONTREAL CHILDREN S HOSPITAL   (Canada)

Author keywords

Amine oxidoreductases; Cardiovascular diseases; Folic acid; Genotype; Homocysteine; Neural tube defects; Vitamins

Indexed keywords

5 METHYLTETRAHYDROFOLIC ACID; 5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); HOMOCYSTEINE; METHIONINE;

CARDIOVASCULAR DISEASE; PLASMA; PREGNANCY; RISK FACTOR;

ADOLESCENT; ADULT; AGE; ALZHEIMER DISEASE; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; ENZYME METABOLISM; ENZYME SYNTHESIS; FEMALE; GENE; GENETIC RISK; GENOTYPE; HUMAN; HYPERHOMOCYSTEINEMIA; MAJOR CLINICAL STUDY; METHYLATION; MTHFR GENE; NEURAL TUBE DEFECT; PREGNANCY COMPLICATION; RISK FACTOR; SPINA BIFIDA; STATISTICAL SIGNIFICANCE; VITAMIN INTAKE;

ADOLESCENT; ADULT; AGE FACTORS; AGED; CARDIOVASCULAR DISEASES; FEMALE; GENOTYPE; HOMOCYSTEINE; HUMANS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; SPINAL DYSRAPHISM;

EID: 0142219380     PISSN: 00029262     EISSN: None     Source Type: Journal    
DOI: 10.1093/aje/kwg234     Document Type: Article

References (30)

1. Boushey CJ, Beresford SA, Omenn GS, et al. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease-probable benefits of increasing folic acid intakes. JAMA 1995;274:1049-57.
2. Ueland PM, Refsum H, Beresford SA, et al. The controversy over homocysteine and cardiovascular risk. Am J Clin Nutr 2000;72:324-32.
3. Selhub J, Jacques PF, Bostom AG, et al. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med 1995;332:286-91.
4. Nygard O, Nordrehaug JE, Refsum H, et al. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997;337:230-6.
5. Bostom AG, Rosenberg IH, Silbershatz, et al. Nonfasting plasma total homocysteine levels and stroke incidence in elderly persons: The Framingham Study. Ann Intern Med 1999;131:352-5.
6. Jacques PF, Bostom AG, Wilson WF, et al. Determinants of plasma total homocysteine concentration in the Framingham offspring cohort. Am J Clin Nutr 2001;73:613-21.
7. Jacques PF, Bostom AG, Williams RR, et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996;93:7-9.
8. Selhub J, Jacques PF, Wilson PW, et al. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993;270:2693-8.
9. Delvin E, Rozen R, Merouani A, et al. Influence of methylenetetrahydrofolate reductase genotype, age, vitamin B-12, and folate status on plasma homocysteine in children. Am J Clin Nutr 2000;72:1469-73.
10. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nature Genet 1995;10:111-13.
11. Brattstrom L, Wilcken DE, Ohrvik J, et al. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease. Circulation 1998;98:2520-6.
12. Guenther BD, Sheppard CA, Tran P, et al. The structure and properties of methylenetetrahydrofolate reductase from Escherichia coli: a model for the role of folate in ameliorating hyperhomocysteinemia in humans. Nat Struct Biol 1999;6:359-65.
13. Yamada K, Chen Z, Rozen R, et al. Effects of common polymorphisms on the properties of recombinant human methylenetetrahydrofolate reductase. Proc Natl Acad Sci U S A 2001;98:14853-8.
14. Hustad S, Ueland PM, Vollset SE, et al. Riboflavin as a determinant of plasma total homocysteine: effect modification by the methylenetetrahydrofolate reductase C677T polymorphism. Clin Chem 2000;46:1065-71.
15. Jacques PF, Kalmbach R, Bagley PJ, et al. The relationship between riboflavin and plasma total homocysteine in the Framingham offspring cohort is influenced by folate status and the C677T transition in the methylenetetrahydrofolate reductase gene. J Nutr 2002;132:283-8.
16. Kluijtmans LA, Van Den Heuvel LP, Boers GH, et al. Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet 1996;58:35-41.
17. Gallagher PM, Meleady R, Shields DC, et al. Homocysteine and risk of premature coronary heart disease: evidence for a common gene mutation. Circulation 1996;94:2154-8.
18. Morita H, Taguchi JI, Kurihara H, et al. Genetic polymorphisms of 5,10-methylenetetrahydrofolate reductase (MTHFR) as a risk factor for coronary artery disease. Circulation 1997;95:2032-6.
19. Van Der Put NM, Steegers-Theunissen RP, Frosst P, et al. Mutated methylenetetrahydrofolate reductase as a risk factor for spina bifida. Lancet 1995;346:1070-1.
20. Botto LD, Yang Q. 5, 10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies: a HuGE review. Am J Epidemiol 2000;151:862-77.
21. Ray JG, Laskin CA. Folic acid and homocysteine metabolism defects and the risk of placental abruption, pre-eclampsia, and spontaneous pregnancy loss: a systematic review. Placenta 1999;20:519-29.
22. Joober R, Benkelfat C, Lal S, et al. Association between the methylenetetrahydrofolate reductase 677C→T missense mutation and schizophrenia. Mol Psychiatry 2000;5:323-6.
23. Fletcher O, Kessling AM. MTHFR: association with arteriosclerotic vascular disease? Hum Genet 1998;103:11-21.
24. Childs B. A logic of disease. In: Scriver CR, Beaudet AL, Sly WS, et al, eds. The metabolic and molecular bases of inherited disease. New York, NY: McGraw-Hill, Inc, 2001:229-58.
25. Mager A, Lalezari S, Shohat T, et al. Methylenetetrahydrofolate reductase genotypes and early-onset coronary artery disease. Circulation 1999;100:2406-10.
26. Christensen B, Arbour L, Tran P, et al. Genetic polymorphisms in methylenetetrahydrofolate reductase and methionine synthase, folate levels in red blood cells, and risk of neural tube defects. Am J Med Genet 1999;84:151-7.
27. Bostom AG, Jacques PF, Nadeau MR, et al. Post-methionine load hyperhomocysteinemia in persons with normal fasting total plasma homocysteine: initial results from the NHLBI Family Heart Study. Atherosclerosis 1995;116:147-51.
28. Singh M, Berger PB, Ting HH, et al. Influence of coronary thrombus on outcome of percutaneous coronary angioplasty in the current era (the Mayo Clinic experience). Am J Cardiol 2001;15:1091-6.
29. Refsum H, Ueland PM, Nygard O, et al. Homocysteine and cardiovascular disease. Annu Rev Med 1998;49:31-62.
30. Ma J, Stampfer MJ, Hennekens CH, et al. Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in US physicians. Circulation 1996;94:2410-16.